inclusion criteria: 1. patients are 18-70 years of age; 2. patients must have at least one of the following risk factors for developing severe covid-19 disease: 1. age 50 to 70 years; 2. obesity (body mass index (bmi) of 30 or greater); 3. hypertension; 4. current smoker; 5. diabetes mellitus (type 1 or type 2); 6. stable cardiac disease. 3. experiencing symptoms of mild to moderate covid-19 not requiring supplemental oxygen; 4. having confirmed infection with sars-cov-2, defined as detection of sars-cov-2 from nasopharyngeal swab or lower respiratory tract specimen; 5. karnofsky performance score ≥70%; 6. enrolled within the first 4 days of onset of symptoms; 7. able and willing to comply with the protocol for duration of the study, including 24 hour hospitalization for study drug administration and monitoring, and compliance with follow-up visit schedule; 8. signed irb approved informed consent.

inclusion criteria: 1. patients are 18-70 years of age; 2. patients must have at least one of the following risk factors for developing severe covid-19 disease: 1. age 50 to 70 years; 2. obesity (body mass index (bmi) of 30 or greater); 3. hypertension; 4. current smoker; 5. diabetes mellitus (type 1 or type 2); 6. stable cardiac disease. 3. experiencing symptoms of mild to moderate covid-19 not requiring supplemental oxygen; 4. having confirmed infection with sars-cov-2, defined as detection of sars-cov-2 from nasopharyngeal swab or lower respiratory tract specimen; 5. karnofsky performance score ≥70%; 6. enrolled within the first 4 days of onset of symptoms; 7. able and willing to comply with the protocol for duration of the study, including 24 hour hospitalization for study drug administration and monitoring, and compliance with follow-up visit schedule; 8. signed irb approved informed consent.

inclusion criteria: patients are 18-70 years of age; patients must have at least one of the following risk factors for developing severe covid-19 disease: age 50 to 70 years; obesity (body mass index (bmi) of 30 or greater); hypertension; current smoker; diabetes mellitus (type 1 or type 2); stable cardiac disease. experiencing symptoms of mild to moderate covid-19 not requiring supplemental oxygen; having confirmed infection with sars-cov-2, defined as detection of sars-cov-2 from nasopharyngeal swab or lower respiratory tract specimen; karnofsky performance score ≥70%; enrolled within the first 4 days of onset of symptoms; able and willing to comply with the protocol for duration of the study, including 24 hour hospitalization for study drug administration and monitoring, and compliance with follow-up visit schedule; signed irb approved informed consent.

inclusion criteria: patients are 18-70 years of age; patients must have at least one of the following risk factors for developing severe covid-19 disease: age 50 to 70 years; obesity (body mass index (bmi) of 30 or greater); hypertension; current smoker; diabetes mellitus (type 1 or type 2); stable cardiac disease. experiencing symptoms of mild to moderate covid-19 not requiring supplemental oxygen; having confirmed infection with sars-cov-2, defined as detection of sars-cov-2 from nasopharyngeal swab or lower respiratory tract specimen; karnofsky performance score ≥70%; enrolled within the first 4 days of onset of symptoms; able and willing to comply with the protocol for duration of the study, including 24 hour hospitalization for study drug administration and monitoring, and compliance with follow-up visit schedule; signed irb approved informed consent.

inclusion criteria: 1. patients are 18-70 years of age; 2. patients must have at least one of the following risk factors for developing severe covid-19 disease: 1. age 50 to 70 years; 2. obesity (body mass index (bmi) of 30 or greater); 3. hypertension; 4. current smoker; 5. diabetes mellitus (type 1 or type 2); 6. stable cardiac disease. 3. experiencing symptoms of mild to moderate covid-19 not requiring supplemental oxygen; 4. having confirmed infection with sars-cov-2, defined as detection of sars-cov-2 from nasopharyngeal swab or lower respiratory tract specimen; 5. karnofsky performance score ≥70%; 6. enrolled within the first 4 days of onset of symptoms; 7. able and willing to comply with the protocol for duration of the study, including 24 hour hospitalization for study drug administration and monitoring, and compliance with follow-up visit schedule; 8. signed irb approved informed consent.

inclusion criteria: 1. patients are 18-70 years of age; 2. patients must have at least one of the following risk factors for developing severe covid-19 disease: 1. age 50 to 70 years; 2. obesity (body mass index (bmi) of 30 or greater); 3. hypertension; 4. current smoker; 5. diabetes mellitus (type 1 or type 2); 6. stable cardiac disease. 3. experiencing symptoms of mild to moderate covid-19 not requiring supplemental oxygen; 4. having confirmed infection with sars-cov-2, defined as detection of sars-cov-2 from nasopharyngeal swab or lower respiratory tract specimen; 5. karnofsky performance score ≥70%; 6. enrolled within the first 4 days of onset of symptoms; 7. able and willing to comply with the protocol for duration of the study, including 24 hour hospitalization for study drug administration and monitoring, and compliance with follow-up visit schedule; 8. signed irb approved informed consent.